[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100324511":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":41,"centralContacts":45,"locations":55,"responsibleParty":76,"collaborators":50,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":50,"enrollmentInfo":88,"targetDuration":50,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":57,"whyStopped":50,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Cedars-Sinai Medical Center","OTHER",[8,15],{"label":9,"type":6,"description":10,"interventionNames":11},"Healthy Volunteers","Approximately 110 healthy male\u002Ffemale adult \"normals\" or \"controls\" will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant.",[12,13,14],"Device: Cardiac MRI","Drug: Contrast","Drug: Beta blocker",{"label":16,"type":6,"description":17,"interventionNames":18},"Coronary Artery Disease (CAD) Patients","40 male\u002Ffemale adult outpatients who are suspected of having or have been diagnosed with coronary artery disease (CAD) will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant.",[12,13,14],[20,27,35],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Cardiac MRI","MRI with\u002Fwithout administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.",[16,9],[26],"Magnetic Resonance Imaging",{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Contrast","The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol\u002Fkg).",[16,9],[33,34],"contrast agent","Gadavist",{"type":28,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Beta blocker","Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.",[16,9],[40],"Metoprolol",[42],{"name":43,"affiliation":5,"role":44},"Debiao Li, PhD","PRINCIPAL_INVESTIGATOR",[46,52],{"name":47,"role":48,"phone":49,"phoneExt":50,"email":51},"Rosalia (Sally) A De Leon","CONTACT","310 423-7758",null,"Rosalia.DeLeon@cshs.org",{"name":43,"role":48,"phone":53,"phoneExt":50,"email":54},"310 423-7743","debiao.li@cshs.org",[56],{"facility":5,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"RECRUITING","Los Angeles","California","90048","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-118.24368,34.05223,{"lat":67,"lon":66},[70,74],{"name":71,"role":48,"phone":72,"phoneExt":50,"email":73},"Rhona Littman","310 423-4387","Rhona.Littman@cshs.org",{"name":43,"role":48,"phone":53,"phoneExt":50,"email":75},"Debiao.Li@cshs.org",{"type":44,"investigatorFullName":43,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":50,"oldOrganization":50},"Director, Biomedical Imaging Research Institute","100324511","coronary-atherosclerosis-t1-weighted-characterization-catch-100324511",false,"NCT03504956","Coronary Atherosclerosis T1-Weighted Characterization (CATCH)","CATCH","Inclusion:\n\n* Healthy Volunteers: male or female ≥ 18 years of age with a BMI\\\u003C30, with no history of cardiovascular disease\n* Patients: Medically stable, male or female ≥ 18 years of age who is have not suspected of having or has been diagnosed with coronary artery disease and undergone stenting or bypass surgery\n\nExclusion:\n\n* Contraindications to MR imaging including mechanically, magnetically, or electrically activated implants, ferromagnetic implants and ferromagnetic foreign bodies, pregnancy.\n* Inability to tolerate MR imaging secondary to an inability to hold breath for a short time or have claustrophobia.\n* Non-compliant with visit instructions, including following procedure instructions\n* Severe allergy to animal dander or animal-instigated asthma\n* Specific to gadolinium-based contrast agents: Renal function test does not meet CSMC standard of care MRI contrast protocol requirements (GFR \\\u003C45ml\u002Fmin) or previous allergic reaction to gadolinium-based contrast agents.\\*\n* Volunteers who have had four or more prior previous gadolinium contrast scan",true,"ALL","18 Years",{"count":89,"type":90},150,"ESTIMATED","INTERVENTIONAL",[93],"NA","This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.",[96],"Coronary Atherosclerosis",[98,99],"MRI technique","High Resolution MRI Technique","2025-08-11",{"date":102,"type":103},"2025-08-14","ACTUAL",{"date":105,"type":103},"2018-07-30",{"date":107,"type":90},"2026-12-31",{"name":5,"class":6},1]